Skip to main content
Premium Trial:

Request an Annual Quote

Genentech to Use Horizon for Cancer Studies

NEW YORK (GenomeWeb News) – Horizon Discovery said today that Genentech will use its technology to develop cancer models for drug discovery programs.

The Cambridge, UK-based company said Genentech will be able to use its GENESIS gene-engineering platform to develop genetically defined human cancer models for cancer studies.

These mutant and normal cell lines, called X-MAN, provide a source of human cell-types that hold specific cancer causing genes plus a matched normal cell as a control. This method could enable development of novel drugs or treatments that target specific patient populations, said Horizon.

Horizon said that under the three-year agreement Genentech will pay it an undisclosed, up-front fee, as well as milestones and renewable fees, as it has in previous agreements between the two companies.

Horizon CEO Chris Torrance said the company’s platform enables users to generate a range of disease models that are “difficult or impossible” to generate using other gene-engineering techniques.

The Scan

Not Immediately Told

The US National Institutes of Health tells lawmakers that one of its grantees did not immediately report that it had developed a more infectious coronavirus, Science says.

Seems Effective in Kids

The Associated Press reports that the Pfizer-BioNTech SARS-CoV-2 vaccine for children appears to be highly effective at preventing symptomatic disease.

Intelligence Warning on Bioeconomy Threats

US intelligence warns over China's focus on technologies and data related to the bioeconomy, the New York Times reports.

PLOS Papers on Campylobacteriosis Sources, Inherited Retinal Dystrophies, Liver Cancer Prognosis

In PLOS this week: approach to uncover source of Campylobacteriosis, genetic risk factors for inherited retinal dystrophies, and more.